Phosphodiesterase inhibitors in psychiatric disorders

[1]  C. Piperi,et al.  Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence , 2022, Molecules.

[2]  H. Schiöth,et al.  Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules , 2022, Frontiers in Pharmacology.

[3]  Jianchun Pan,et al.  Inhibition of Phosphodiesterase 2 Ameliorates Post-Traumatic Stress–Induced Alcohol Intake Disorder by Regulating cAMP/cGMP Signaling , 2022, The international journal of neuropsychopharmacology.

[4]  A. Tanskanen,et al.  Allopurinol, dipyridamole and calcium channel blockers in the treatment of bipolar disorder - A nationwide cohort study. , 2022, Journal of Affective Disorders.

[5]  A. Martín-Santiago,et al.  Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis , 2022, Current therapeutic research, clinical and experimental.

[6]  A. El-Sakka,et al.  Pharmaceutical management of sexual dysfunction in men on antidepressant therapy , 2022, Expert opinion on pharmacotherapy.

[7]  R. Reis,et al.  Female Sexual Dysfunctions: an overview on the available therapeutic interventions. , 2022, Minerva obstetrics and gynecology.

[8]  S. Akhondzadeh,et al.  Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial , 2022, Psychopharmacology.

[9]  S. Akhondzadeh,et al.  Pentoxifylline for treatment of major depression after percutaneous coronary intervention or coronary artery bypass grafting: A randomized, double-blind, placebo-controlled trial. , 2021, Journal of psychosomatic research.

[10]  Esraa M. Mosalam,et al.  Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder , 2021, CNS neuroscience & therapeutics.

[11]  I. Cifre,et al.  Psychological Distress in Erectile Dysfunction: The Moderating Role of Attachment , 2021, Sexual medicine.

[12]  M. Mehta,et al.  Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia , 2021, Journal of psychopharmacology.

[13]  M. Scheunemann,et al.  Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016 , 2021, International journal of molecular sciences.

[14]  S. Akhondzadeh,et al.  Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial , 2021, International clinical psychopharmacology.

[15]  B. Mulsant,et al.  Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response , 2021, Translational Psychiatry.

[16]  Todor V. Gerdjikov,et al.  Phosphodiesterase type 1 inhibition alters medial prefrontal cortical activity during goal-driven behaviour and partially reverses neurophysiological deficits in the rat phencyclidine model of schizophrenia , 2021, Neuropharmacology.

[17]  B. Bardoni,et al.  Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders , 2021, Molecular Psychiatry.

[18]  J. Prickaerts,et al.  PDE inhibition in distinct cell types to reclaim the balance of synaptic plasticity , 2021, Theranostics.

[19]  Haitao Wang,et al.  Inhibition of phosphodiesterase-4 suppresses HMGB1/RAGE signaling pathway and NLRP3 inflammasome activation in mice exposed to chronic unpredictable mild stress , 2020, Brain, Behavior, and Immunity.

[20]  T. Zhu.  Challenges of Psychiatry Drug Development and the Role of Human Pharmacology Models in Early Development—A Drug Developer's Perspective , 2021, Frontiers in Psychiatry.

[21]  Jianchun Pan,et al.  Phosphodiesterase-2 inhibitor reverses post-traumatic stress induced fear memory deficits and behavioral changes via cAMP/cGMP pathway. , 2020, European journal of pharmacology.

[22]  D. Ffytche,et al.  The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial , 2020, Journal of psychopharmacology.

[23]  T. van Groen,et al.  Dominant-Negative Attenuation of cAMP-Selective Phosphodiesterase PDE4D Action Affects Learning and Behavior , 2020, International journal of molecular sciences.

[24]  M. Sakharkar,et al.  Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. , 2020, Pharmacological research.

[25]  K. Hashimoto,et al.  Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor MT-3014 in rats , 2020, Pharmacology Biochemistry and Behavior.

[26]  Yosra Magdy,et al.  Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome. , 2020, Life sciences.

[27]  M. Memo,et al.  Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist , 2020, ACS chemical neuroscience.

[28]  J. Prickaerts,et al.  Persistence of the extinction of fear memory requires late-phase cAMP/PKA signaling in the infralimbic cortex , 2020, Neurobiology of Learning and Memory.

[29]  Y. Kuang,et al.  The Role of BDNF on Neural Plasticity in Depression , 2020, Frontiers in Cellular Neuroscience.

[30]  Kang Liu,et al.  The decline in sexual function, psychological disorders (anxiety and depression) and life satisfaction in older men: A cross‐sectional study in a hospital‐based population , 2020, Andrologia.

[31]  Lack of Efficacy , 2020, Definitions.

[32]  Nidhi Kaushal,et al.  Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents , 2019, The international journal of neuropsychopharmacology.

[33]  Vikas K. Dawra,et al.  Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute Schizophrenia. , 2019, Journal of clinical psychopharmacology.

[34]  G. Baillie,et al.  Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches , 2019, Biochemical Society transactions.

[35]  Ayaka Tatara,et al.  A Novel Phosphodiesterase 1 Inhibitor DSR-141562 Exhibits Efficacies in Animal Models for Positive, Negative, and Cognitive Symptoms Associated with Schizophrenia , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[36]  K. McLaughlin,et al.  Impaired hippocampus-dependent associative learning as a mechanism underlying PTSD: A meta-analysis , 2019, Neuroscience & Biobehavioral Reviews.

[37]  K. Hashimoto,et al.  Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents , 2019, Pharmacology Biochemistry and Behavior.

[38]  L. Xue,et al.  Fear renewal activates cyclic adenosine monophosphate signaling in the dentate gyrus , 2019, Brain and behavior.

[39]  J. O'Donnell,et al.  The antidepressant- and anxiolytic-like effects of resveratrol: Involvement of phosphodiesterase-4D inhibition , 2019, Neuropharmacology.

[40]  E. Pickering,et al.  A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia. , 2019, Journal of clinical psychopharmacology.

[41]  K. Aertgeerts,et al.  Target Engagement of a Phosphodiesterase 2A Inhibitor Affecting Long-Term Memory in the Rat , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[42]  K. Alzoubi,et al.  Molecular targets for the interactive effect of etazolate during post-traumatic stress disorder: Role of oxidative stress, BDNF and histones , 2019, Behavioural Brain Research.

[43]  J. O'Donnell,et al.  Reduced phosphodiesterase-2 activity in the amygdala results in anxiolytic-like effects on behavior in mice , 2019, Journal of psychopharmacology.

[44]  Haitao Wang,et al.  FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[45]  Anissa Abi-Dargham,et al.  Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms , 2019, Trends in Neurosciences.

[46]  Haitao Wang,et al.  Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors and Prevents Dendritic Spine Loss in Mice Hippocampi , 2018, The international journal of neuropsychopharmacology.

[47]  Min Mao,et al.  Synaptic Plasticity in PTSD and associated Comorbidities: The Function and Mechanism for Diagnostics and Therapy. , 2019, Current pharmaceutical design.

[48]  M. Mehta,et al.  An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients , 2018, Psychopharmacology.

[49]  Heng Li,et al.  Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases , 2018, Front. Pharmacol..

[50]  Hai-bin Luo,et al.  A novel PDE9 inhibitor WYQ‐C36D ameliorates corticosterone‐induced neurotoxicity and depression‐like behaviors by cGMP‐CREB‐related signaling , 2018, CNS neuroscience & therapeutics.

[51]  Xiongwei Zhu,et al.  Inhibition of phosphodiesterase 2 reverses gp91phox oxidase-mediated depression- and anxiety-like behavior , 2018, Neuropharmacology.

[52]  T. Mostafa,et al.  The Phosphodiesterase Inhibitor Pentoxifylline as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial , 2018, Psychotherapy and Psychosomatics.

[53]  P. Lazarovici,et al.  cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia , 2018, Front. Mol. Neurosci..

[54]  J. O'Donnell,et al.  The neuroprotective and antidepressant‐like effects of Hcyb1, a novel selective PDE2 inhibitor , 2018, CNS neuroscience & therapeutics.

[55]  I. Liberzon,et al.  Single-Prolonged Stress: A Review of Two Decades of Progress in a Rodent Model of Post-traumatic Stress Disorder , 2018, Front. Psychiatry.

[56]  K. Alzoubi,et al.  Pentoxifylline prevents post-traumatic stress disorder induced memory impairment , 2018, Brain Research Bulletin.

[57]  N. Goyal,et al.  Sensory Gating Deficits and their Clinical Correlates in Drug-Free/Drug-Naive Patients with Schizophrenia , 2018, Indian journal of psychological medicine.

[58]  Haitao Wang,et al.  Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of p38 and JNK Signaling Pathways , 2018, International journal of molecular sciences.

[59]  M. Corsi,et al.  Combined treatment with a selective PDE10A inhibitor TAK‐063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic‐like effects without affecting plasma prolactin levels and cataleptic responses in rodents , 2017, Pharmacology research & perspectives.

[60]  T. van Groen,et al.  Altered phosphorylation, electrophysiology, and behavior on attenuation of PDE4B action in hippocampus , 2017, BMC Neuroscience.

[61]  K. Alzoubi,et al.  Evaluating the protective effect of etazolate on memory impairment, anxiety- and depression-like behaviors induced by post traumatic stress disorder , 2017, Brain Research Bulletin.

[62]  M. Dubovický,et al.  Animal tests for anxiety-like and depression-like behavior in rats , 2017, Interdisciplinary toxicology.

[63]  Ying Xu,et al.  Attenuation of ethanol abstinence-induced anxiety- and depressive-like behavior by the phosphodiesterase-4 inhibitor rolipram in rodents , 2017, Psychopharmacology.

[64]  S. Akhondzadeh,et al.  Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double‐blind, placebo‐controlled study , 2017, Human psychopharmacology.

[65]  Didier Y. R. Stainier,et al.  Genetic compensation: A phenomenon in search of mechanisms , 2017, PLoS genetics.

[66]  W. A. Carlezon Jr.,et al.  Behavioral methods to study anxiety in rodents , 2017, Dialogues in clinical neuroscience.

[67]  G. Mengod,et al.  Phosphodiesterase-7 inhibition affects accumbal and hypothalamic thyrotropin-releasing hormone expression, feeding and anxiety behavior of rats , 2017, Behavioural Brain Research.

[68]  E. Kaltenthaler,et al.  Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis. , 2017, European urology focus.

[69]  J. Prickaerts,et al.  The phosphodiesterase type 2 inhibitor BAY 60‐7550 reverses functional impairments induced by brain ischemia by decreasing hippocampal neurodegeneration and enhancing hippocampal neuronal plasticity , 2017, The European journal of neuroscience.

[70]  M. Gurney,et al.  Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System , 2017, Scientific Reports.

[71]  B. Ibrahim,et al.  PDE11A negatively regulates lithium responsivity , 2016, Molecular Psychiatry.

[72]  Han-Ting Zhang,et al.  Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence. , 2017, Advances in neurobiology.

[73]  Robert C. Thompson,et al.  The microRNA network is altered in anterior cingulate cortex of patients with unipolar and bipolar depression. , 2016, Journal of psychiatric research.

[74]  Matthew A. Palmer,et al.  The centrality of fear extinction in linking risk factors to PTSD: A narrative review , 2016, Neuroscience & Biobehavioral Reviews.

[75]  P. Faridi,et al.  Comparison of the Effects of Elaeagnus angustifolia Flower Capsule and Sildenafil Citrate Tablet on Anxiety Resulting From Sexual Dysfunction in Women Referring to the Selected Clinics of Shiraz University of Medical Sciences , 2016, Journal of evidence-based complementary & alternative medicine.

[76]  J. Prickaerts,et al.  Rolipram improves cognition, reduces anxiety- and despair-like behaviors and impacts hippocampal neuroplasticity after transient global cerebral ischemia , 2016, Neuroscience.

[77]  Steven V. Fox,et al.  Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity , 2016, Psychopharmacology.

[78]  M. Miyamoto,et al.  TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms , 2016, Neuropsychopharmacology.

[79]  E. Chang,et al.  Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse , 2016, Neuron.

[80]  J. Roder,et al.  Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition , 2017, Neuropsychopharmacology.

[81]  Ha Neui Kim,et al.  Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke , 2016, Psychopharmacology.

[82]  C. Bundgaard,et al.  Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A. , 2015, European journal of pharmacology.

[83]  Maha A E Ahmed,et al.  Lipoic acid and pentoxifylline mitigate nandrolone decanoate-induced neurobehavioral perturbations in rats via re-balance of brain neurotransmitters, up-regulation of Nrf2/HO-1 pathway, and down-regulation of TNFR1 expression , 2015, Hormones and Behavior.

[84]  田原 康玄,et al.  生活習慣病とgenome-wide association study , 2015 .

[85]  R. Carhart-Harris,et al.  Drug models of schizophrenia , 2015, Therapeutic advances in psychopharmacology.

[86]  T. Maniatis,et al.  An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex , 2014, The Journal of Neuroscience.

[87]  L. Shin,et al.  From Pavlov to PTSD: The extinction of conditioned fear in rodents, humans, and anxiety disorders , 2014, Neurobiology of Learning and Memory.

[88]  J. O'Donnell,et al.  Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: Involvement of antioxidant and anti-apoptotic mechanisms , 2014, Behavioural Brain Research.

[89]  C. Davies,et al.  GSK356278, a Potent, Selective, Brain-Penetrant Phosphodiesterase 4 Inhibitor That Demonstrates Anxiolytic and Cognition-Enhancing Effects without Inducing Side Effects in Preclinical Species , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[90]  R. D'Hooge,et al.  Improved Long-Term Memory via Enhancing cGMP-PKG Signaling Requires cAMP-PKA Signaling , 2014, Neuropsychopharmacology.

[91]  Qinwen Wang,et al.  Antidepressant-like effects of the phosphodiesterase-4 inhibitor etazolate and phosphodiesterase-5 inhibitor sildenafil via cyclic AMP or cyclic GMP signaling in mice , 2014, Metabolic Brain Disease.

[92]  J. Zhang,et al.  Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice , 2014, Neuroscience.

[93]  Y. Shim,et al.  Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study , 2014, International Journal of Impotence Research.

[94]  C. Bundgaard,et al.  In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia , 2014, Psychopharmacology.

[95]  O. Amaral,et al.  A phosphodiesterase 4-controlled switch between memory extinction and strengthening in the hippocampus , 2014, Front. Behav. Neurosci..

[96]  S. Endo,et al.  Cilostazol improves hippocampus-dependent long-term memory in mice , 2014, Psychopharmacology.

[97]  Dawn M. Toolan,et al.  Genetic Deletion and Pharmacological Inhibition of Phosphodiesterase 10A Protects Mice From Diet-Induced Obesity and Insulin Resistance , 2013, Diabetes.

[98]  Stephan Heckers,et al.  Definition and description of schizophrenia in the DSM-5 , 2013, Schizophrenia Research.

[99]  S. Bhatt,et al.  Anxiolytic-like effect of etazolate, a type 4 phosphodiesterase inhibitor in experimental models of anxiety. , 2013, Indian journal of experimental biology.

[100]  Jack Y. B. Lee,et al.  Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. , 2013, European urology.

[101]  S. Bhatt,et al.  Etazolate, a phosphodiesterase 4 inhibitor reverses chronic unpredictable mild stress-induced depression-like behavior and brain oxidative damage , 2013, Pharmacology Biochemistry and Behavior.

[102]  J. Roder,et al.  Dual inhibitor of PDE7 and GSK-3 – VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice , 2013, Neuropharmacology.

[103]  R. Miano,et al.  Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? a systematic review and meta-analysis. , 2012, The journal of sexual medicine.

[104]  D. Pandey,et al.  Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitor--an approach using rodent behavioral antidepressant tests battery. , 2012, European journal of pharmacology.

[105]  C. Vorhees,et al.  A new model of Pde4d deficiency: genetic knock‐down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects , 2012, Genes, brain, and behavior.

[106]  E. Atlantis,et al.  Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis. , 2012, The journal of sexual medicine.

[107]  L. Schalkwyk,et al.  Depression‐Related Behavioral Tests , 2012, Current protocols in mouse biology.

[108]  Eric R Kandel,et al.  The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB , 2012, Molecular Brain.

[109]  Clas Linnman,et al.  Resting amygdala and medial prefrontal metabolism predicts functional activation of the fear extinction circuit. , 2012, The American journal of psychiatry.

[110]  J. Roder,et al.  Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice , 2012, Neuropharmacology.

[111]  C. Lugnier,et al.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments , 2012, British journal of pharmacology.

[112]  G. Wegener,et al.  Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats , 2012, Metabolic Brain Disease.

[113]  U. Egerland,et al.  Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test , 2012, Psychopharmacology.

[114]  B. Muthén,et al.  Genome-Wide Association Study in Bipolar Patients Stratified by Co-Morbidity , 2011, PloS one.

[115]  L. R. Potter,et al.  Guanylyl cyclase structure, function and regulation. , 2011, Cellular signalling.

[116]  C A Jones,et al.  Animal models of schizophrenia , 2011, British journal of pharmacology.

[117]  A. Blokland,et al.  Enhanced long-term depression and impaired reversal learning in phosphodiesterase 4B-knockout (PDE4B −/−) mice , 2011, Neuropharmacology.

[118]  Nausheen Alam,et al.  Hypophagic and hypolocomotive effects of metachloro phenyl piperazine in rats treated with theophylline and caffeine. , 2011, Pakistan Journal of Pharmaceutical Sciences.

[119]  S. Kennedy,et al.  A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder , 2011, International clinical psychopharmacology.

[120]  Y. Solak,et al.  Effects of sildenafil and vardenafil treatments on sleep quality and depression in hemodialysis patients with erectile dysfunction , 2011, International Journal of Impotence Research.

[121]  L. O’Driscoll.  Gene Expression Profiling , 2011, Methods in Molecular Biology.

[122]  E. Karran,et al.  Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues , 2010, Neuropharmacology.

[123]  Mark A. Smith,et al.  Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective. , 2010, The international journal of neuropsychopharmacology.

[124]  S. Hofmann,et al.  The type IV phosphodiesterase inhibitor rolipram disturbs expression and extinction of conditioned fear in mice , 2010, Neuropharmacology.

[125]  G. Wegener,et al.  Investigating the role of protein kinase-G in the antidepressant-like response of sildenafil in combination with muscarinic acetylcholine receptor antagonism , 2010, Behavioural Brain Research.

[126]  Ingrid Agartz,et al.  Association study of PDE4B gene variants in scandinavian schizophrenia and bipolar disorder multicenter case–control samples , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[127]  J. Roder,et al.  A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment , 2010, Psychopharmacology.

[128]  Chunfu Wu,et al.  Regulation of amygdalar PKA by β-arrestin-2/phosphodiesterase-4 complex is critical for fear conditioning , 2009, Proceedings of the National Academy of Sciences.

[129]  T. Comery,et al.  Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia , 2009, Journal of Pharmacology and Experimental Therapeutics.

[130]  A. Simons,et al.  Sexual dysfunction in depression and anxiety: conceptualizing sexual dysfunction as part of an internalizing dimension. , 2009, Clinical psychology review.

[131]  Nam Cheol Park,et al.  Sildenafil citrate 100 mg starting dose in men with erectile dysfunction in an international, double-blind, placebo-controlled study: effect on the sexual experience and reducing feelings of anxiety about the next intercourse attempt. , 2009, The journal of sexual medicine.

[132]  J. O'Donnell,et al.  Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 (PDE4) inhibitor rolipram on behavior depend on cyclic AMP-response element binding protein (CREB)-mediated neurogenesis in the hippocampus , 2009, Neuropsychopharmacology.

[133]  M. Wong,et al.  Phosphodiesterase genes and antidepressant treatment response: A review , 2009, Annals of medicine.

[134]  T. Comery,et al.  Phosphodiesterase 10 A Inhibitor Activity in Preclinical Models of the Positive , Cognitive , and Negative Symptoms of Schizophrenia , 2009 .

[135]  S. Fatemi,et al.  Phosphodiesterase-4A expression is reduced in cerebella of patients with bipolar disorder , 2008, Psychiatric genetics.

[136]  G. Schafe,et al.  The NO-cGMP-PKG signaling pathway regulates synaptic plasticity and fear memory consolidation in the lateral amygdala via activation of ERK/MAP kinase. , 2008, Learning & memory.

[137]  J. Soares,et al.  A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. , 2008, The Journal of clinical psychiatry.

[138]  D. Goff,et al.  A placebo-controlled study of sildenafil effects on cognition in schizophrenia , 2008, Psychopharmacology.

[139]  J. O'Donnell,et al.  Reversal of Oxidative Stress-Induced Anxiety by Inhibition of Phosphodiesterase-2 in Mice , 2008, Journal of Pharmacology and Experimental Therapeutics.

[140]  A. Blokland,et al.  Enhanced long‐term potentiation and impaired learning in phosphodiesterase 4D‐knockout (PDE4D−/−) mice , 2008, The European journal of neuroscience.

[141]  S. Siegel,et al.  Antipsychotic-Like Properties of Phosphodiesterase 4 Inhibitors: Evaluation of 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with Auditory Event-Related Potentials and Prepulse Inhibition of Startle , 2008, Journal of Pharmacology and Experimental Therapeutics.

[142]  D. Klein,et al.  An Open-Label Pilot Study to Evaluate the Efficacy of Sildenafil Citrate in Middle-Aged Men With Late-Onset Dysthymia , 2008, The Journal of nervous and mental disease.

[143]  H. Robertson,et al.  Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice , 2008, European Neuropsychopharmacology.

[144]  S. Paciga,et al.  PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia , 2008, Schizophrenia Research.

[145]  J. Siuciak,et al.  Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme , 2008, Psychopharmacology.

[146]  G. Jenkins,et al.  Variants in PDE11A and PDE1A are not associated with citalopram response , 2007, Molecular Psychiatry.

[147]  William A Weiss,et al.  Recognizing and exploiting differences between RNAi and small-molecule inhibitors. , 2007, Nature chemical biology.

[148]  James C. Overholser,et al.  Gene Expression Profiling in Postmortem Prefrontal Cortex of Major Depressive Disorder , 2007, The Journal of Neuroscience.

[149]  J. Siuciak,et al.  Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme , 2007, Psychopharmacology.

[150]  M. Fava,et al.  Open-label sildenafil treatment of partial and non-responders to double-blind treatment in men with antidepressant-associated sexual dysfunction , 2007, International Journal of Impotence Research.

[151]  B. Harvey,et al.  Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies , 2007, Journal of Neural Transmission.

[152]  R. Cantor,et al.  Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response , 2006, Proceedings of the National Academy of Sciences.

[153]  F. Menniti,et al.  Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function , 2006, Neuropharmacology.

[154]  F. Montorsi,et al.  Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. , 2006, The American journal of psychiatry.

[155]  E. Murphy,et al.  PDE10A inhibition reverses subchronic PCP‐induced deficits in attentional set‐shifting in rats , 2005, The European journal of neuroscience.

[156]  J. Boissel,et al.  Phosphodiesterase III inhibitors for heart failure. , 2005, The Cochrane database of systematic reviews.

[157]  S. Kapur,et al.  A Model of Antipsychotic Action in Conditioned Avoidance: A Computational Approach , 2004, Neuropsychopharmacology.

[158]  G. Plomteux,et al.  Is Phosphodiesterase inhibition a new mechanism of antidepressant action? , 1988, European archives of psychiatry and neurological sciences.

[159]  J. O'Donnell,et al.  Antidepressant-like Profile and Reduced Sensitivity to Rolipram in Mice Deficient in the PDE4D Phosphodiesterase Enzyme , 2002, Neuropsychopharmacology.

[160]  M. Fava,et al.  Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. , 2002, Urology.

[161]  G. Morgia,et al.  Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. , 2002, European urology.

[162]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[163]  R. Rosen,et al.  Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. , 2001, The American journal of psychiatry.

[164]  W. Langhans,et al.  Inhibition of TNF-alpha production contributes to the attenuation of LPS-induced hypophagia by pentoxifylline. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[165]  Scott T. Wong,et al.  Cross Talk between ERK and PKA Is Required for Ca2+ Stimulation of CREB-Dependent Transcription and ERK Nuclear Translocation , 1998, Neuron.

[166]  E. Vizi,et al.  Suppression of IL‐12 production by phosphodiesterase inhibition in murine endotoxemia is IL‐10 independent , 1998, European journal of immunology.

[167]  J. O'fallon,et al.  Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  M. Stein,et al.  Lack of efficacy of the adenosine reuptake inhibitor dipyridamole in the treatment of anxiety disorders , 1993, Biological Psychiatry.

[169]  W. Fleischhacker,et al.  A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. , 1992, Neuropsychobiology.